Your session is about to expire
← Back to Search
Study Summary
This trial will test if a new vaccine can prevent seasonal influenza in adults aged 50 and over.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 885 Patients • NCT04956575Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are willing and physically able to comply with follow-up procedures.You have tested positive for the flu in the past 6 months.You don't know if you got a flu shot last year.You had a serious allergic reaction to mRNA or influenza vaccines in the past.You had a flu shot or a different experimental flu shot within the last 180 days.You have been in close contact with someone who has been diagnosed with the flu or who has taken antiviral medicine for the flu in the past 5 days before the screening visit.You have taken strong immune-suppressing drugs for more than 14 days in the past 6 months, or you expect to need these drugs while in the study. Using inhaled, nasal, or topical steroids is okay.You have been in close contact with someone who has had COVID-19 or tested positive for the virus in the last 10 days.
- Group 1: mRNA-1010
- Group 2: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we presently enrolling people in this study?
"Yes, this information is available on the government-run website clinicaltrials.gov. The study was created on 9/14/2022 and updated as recently as 9/30/2022."
Is this research being conducted at more than one facility in the city?
"One hundred different medical centres are running this study. If you wish to enroll, try and choose a location near you from the list of one hundred clinics, which can be found in Riverside, Omaha, Suffolk and other cities."
How many people are part of this clinical study?
"To complete this trial, 23000 individuals who meet the pre-determined requirements must participate. Trial sites include Benchmark Research-Texas in Riverside, California and Papillon Research Centre in Omaha, Nebraska."
When will mRNA-1010 be available for public consumption?
"There is ample evidence to support the safety of mRNA-1010, as this medication has progressed to a Phase 3 trial."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger